First Tracks Biotherapeutics, Inc.
TRAX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002091349
In the last 90 days, First Tracks Biotherapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 150 institutions reported holding it in 13F filings for Q2 2026, worth $685.8M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 11, 2026
- $2.12B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $1.76M in total
- 1
- 13F holdersQ2 2026, +150 vs. previous quarter
- 150
- 13F valueReported value at the end of Q2 2026
- $685.8M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 5.06M
- Shares sold short
- Change
- −1.90M
- −27.3% vs. previous
- Days to cover
- 6.52
- At average daily volume
Superinvestors holding TRAX, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding TRAX at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by First Tracks Biotherapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 4, 2026 (view filing)4:25 PM ET | Sep 2 | 2 days | Ware J. AnthonyDirector | SSale | −39.3K | $44.78 | −$1.76M | −71.5%15.7K after | |
| Apr 22, 2026 (view filing) | Apr 20 | 2 days | EcoR1 Capital, LLC10% Owner | SSale | +4.71M | $13.81 | +$65.0M | New position3.17M after |
Top 10 13F holders, Q2 2026
See all 150 holdersThe largest institutional positions in First Tracks Biotherapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 3,174,519 | $63.9M | 3.17% | +3,174,519 | New |
| TCG Crossover Management, LLC | 2,895,304 | $58.3M | 1.40% | +2,895,304 | New |
| FMR LLC | 2,054,127 | $41.3M | 0.00% | +2,054,127 | New |
| Affinity Asset Advisors, LLC | 2,032,012 | $40.9M | 2.00% | +2,032,012 | New |
| BlackRock, Inc. | 1,963,541 | $39.5M | 0.00% | +1,963,541 | New |
| Trails Edge Capital Partners, LP | 1,514,000 | $30.5M | 4.84% | +1,514,000 | New |
| State Street Corp | 1,512,896 | $30.4M | 0.00% | +1,512,896 | New |
| Vanguard Capital Management LLC | 1,451,909 | $29.2M | 0.00% | +1,451,909 | New |
| Jupiter Topco LLC | 1,091,464 | $22.0M | 0.01% | +1,091,464 | New |
| Vestal Point Capital, LP | 1,013,000 | $20.4M | 0.48% | +1,013,000 | New |
Holders of 5% or more of TRAX
See all 6 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of First Tracks Biotherapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| FMR LLC | 13G/A | 15.00%6.30M shares | +9.10 ppfrom 5.90% | Aug 6, 20262 filings | Nov 6, 2026 | SEC |
| EcoR1 Capital, LLC | 13G | 9.10%3.17M shares | New | Apr 22, 20261 filing | Apr 22, 2026 | SEC |
| TCG Crossover GP II, LLC | 13G | 8.30%2.90M shares | New | Aug 14, 20261 filing | Aug 14, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 7.20%2.56M shares | +1.70 ppfrom 5.50% | Jul 28, 20262 filings | Oct 27, 2026 | SEC |
| Sirenia Capital Management LP | 13G | 7.20%2.50M shares | New | Aug 14, 20261 filing | Aug 14, 2026 | SEC |